Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:21 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,012 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adverse Events Clear all
Recruiting No phase listed Observational

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

NCT06283927
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, Recurrent Glioblastoma, Astrocytoma, Malignant, Astrocytoma of Brain
Interventions
Re-resection, Temozolomide, Lomustine, Re-irradiation, Experimental therapy, Best supportive care
Procedure · Drug · Radiation + 1 more
Lead sponsor
Jasper Gerritsen
Other
Eligibility
18 Years to 90 Years
Enrollment
464 participants
Timeline
2023 – 2028
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Nov 3, 2026, 6:21 AM EST
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
58
States / cities
Fresno, California • San Diego, California • Santa Barbara, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 3, 2026, 6:21 AM EST
Recruiting No phase listed Observational

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Multiple Myeloma
Interventions
Audio Tasks
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 6:21 AM EST
Completed No phase listed Observational Results available

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

NCT03223428
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Xermelo
Drug
Lead sponsor
TerSera Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Nov 3, 2026, 6:21 AM EST
Active, not recruiting Phase 2 Interventional

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

NCT05034536
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Pembrolizumab, Infliximab, Placebo, Relatlimab, Nivolumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 3, 2026, 6:21 AM EST
Recruiting No phase listed Observational

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

NCT06151730
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 3, 2026, 6:21 AM EST
Completed Not applicable Interventional Results available

Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer

NCT00328783
View directory record Official record
Conditions
Breast Cancer
Interventions
Active Breathing Coordinator (ABC), Radiation Therapy
Device · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Nov 3, 2026, 6:21 AM EST
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig (ABBV-383)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 3, 2026, 6:21 AM EST
Completed Not applicable Interventional

Telehealth and Memory Study

NCT04586530
View directory record Official record
Conditions
Chemotherapy-related Cognitive Dysfunction
Interventions
Memory and Attention Adaptation Training (MAAT), Supportive Therapy (ST)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 3, 2026, 6:21 AM EST
Recruiting Phase 1Phase 2 Interventional

Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository

NCT06789601
View directory record Official record
Conditions
Malignancy, Immune Related Adverse Events
Interventions
Informatics system for eligibility monitoring, Standard eligibility monitoring
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Nov 3, 2026, 6:21 AM EST
Recruiting Phase 1 Interventional

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

NCT07241039
View directory record Official record
Conditions
Advanced Squamous Tumors
Interventions
ABBV-711, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 3, 2026, 6:21 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Lutikizumab, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
48
States / cities
Chula Vista, California • Coronado, California • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Nov 3, 2026, 6:21 AM EST
Completed No phase listed Observational

Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

NCT02158637
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
9
States / cities
Orange, California • Hartford, Connecticut • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Nov 3, 2026, 6:21 AM EST
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

NCT07278336
View directory record Official record
Conditions
Ovarian Cancer
Interventions
ABBV-901, Bevacizumab, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 6:21 AM EST
Completed No phase listed Observational

Cardiovascular Function in Acute Leukemia

NCT03760237
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphoid, Acute, Cardiotoxicity
Interventions
observation only
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Nov 3, 2026, 6:21 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of BabyGentleStick- Adult Pilot Study

NCT02947646
View directory record Official record
Conditions
Lack of Adverse Events, Reduced Pain Response
Interventions
BabyGentleStick™ ON, BabyGentleStick™ OFF
Device
Lead sponsor
Actuated Medical, Inc.
Industry
Eligibility
18 Years to 29 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Nov 3, 2026, 6:21 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Acute Effects of Cannabigerol

NCT05257044
View directory record Official record
Conditions
Focus: To Examine Acute Effects of CBG on Anxiety, Stress, and Cognition
Interventions
Cannabigerol, Placebo
Drug · Other
Lead sponsor
Washington State University
Other
Eligibility
21 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pullman, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 3, 2026, 6:21 AM EST
Completed Phase 2 Interventional Results available

Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

NCT02312934
View directory record Official record
Conditions
Chemo Brain, Chemotherapy-related Cognitive Impairment, Chemo Fog, Breast Cancer, Chemobrain
Interventions
Transdermal nicotine, Placebo Transdermal Patch
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Nov 3, 2026, 6:21 AM EST
Active, not recruiting Not applicable Interventional

Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors

NCT01049230
View directory record Official record
Conditions
Germ Cell Tumor, Central Nervous System Germ Cell Tumor
Interventions
Proton Beam radiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Years to 25 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 6:21 AM EST
Completed Phase 2Phase 3 Interventional

Improving Safety by Basic Computerizing Outpatient Prescribing

NCT01091038
View directory record Official record
Conditions
Adverse Drug Events
Interventions
Basic Clinical Decision Support, Routine Care
Other
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
228 participants
Timeline
2001 – 2007
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Nov 3, 2026, 6:21 AM EST
Completed Phase 2 Interventional

DOXIL for Consolidation Therapy in Ovarian Cancer.

NCT00248248
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
liposomal doxorubicin
Drug
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Nov 3, 2026, 6:21 AM EST
Withdrawn No phase listed Observational

Adverse Events With Magnesium Sulfate

NCT00005448
View directory record Official record
Conditions
Lung Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Up to 100 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Nov 3, 2026, 6:21 AM EST
Not yet recruiting Not applicable Interventional

Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events

NCT07767448
View directory record Official record
Conditions
Cancer
Interventions
La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash, La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream, La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 3, 2026, 6:21 AM EST
Completed Phase 4 Interventional

The Effects of Nexium on the Side Effects Associated With a Colonoscopy Prep

NCT00225238
View directory record Official record
Conditions
Nausea, Vomiting, Abdominal Pain
Interventions
esomeprazole (PPI)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Nov 3, 2026, 6:21 AM EST